METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS

• US 20090297488A1
• Filed: 06/29/2009
• Published: 12/03/2009
• Est. Priority Date: 12/07/2001
• Status: Abandoned Application

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Lorem Vascular Pte. Ltd.
• Inventors: Hedrick, Marc H, Fraser, John K, Daniels, Eric
• Application Number:
  US12/494,211
• Publication Number:
  US 20090297488A1
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 2430/00 Materials or treatment for tissue regeneration
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2506/1384 from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 Vascular Endothelial cells

Abstract

Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.

Claims

1. A method for treating peripheral vascular disease (PVD) in a patient, comprising:

identifying a patient with PVD; and

providing to the patient by injection an amount of a concentrated population of cells comprising adipose-derived stem cells that is sufficient to restore blood flow to an ischemic region.

2. The method of claim 1, further comprising providing an additive to said concentrated population of cells comprising adipose-derived stem cells.

3. The method of claim 1, wherein said patient is human.

4. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells further comprises adipose-derived progenitor cells.

5. The method of claim 1, wherein said patient suffers from a defect or disorder of a blood vessel.

6. The method of claim 1, wherein said patient suffers from Peripheral Artery Disease (PAD).

7. The method of claim 1, wherein said patient suffers from at least one disease or disorder selected from the group consisting of arteriosclerosis, traumatic injury of vessels and inflammatory arteritides.

8. The method of claim 1, wherein said patient suffers from a defect or disorder of extracoronary tissue of the patient.

9. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said patient in multiple doses.

10. The method of claim 1, further comprising providing one or more angiogenic factors to said patient or to said concentrated population of cells comprising adipose-derived stem cells.

11. The method of claim 1, further comprising providing one or more immunosuppressive drugs to said patient or to said concentrated population of cells comprising adipose-derived stem cells.

12. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said patient via at least one of an intravenous, intramuscular or subcutaneous administration route.

13. The method of claim 1, wherein the concentrated population of cells comprising adipose-derived stem cells is provided to the patient'"'"'s vasculature.

14. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to being provided to the patient.

15. The method of claim 14, wherein the cell culture is performed on a scaffold.

16. The method of claim 15, wherein the scaffold is resorbable in vivo.

17. The method of claim 1, wherein said concentrated population of adipose-derived stem cells is modified by gene transfer.

18. The method of claim 17, wherein the modification alters angiogenesis in said patient.

19. The method of claim 17, wherein the modification improves oxygen supply of pre-existent small blood vessels in said patient.

20. The method of claim 17, wherein the modification alters the homing properties of the concentrated population of cells comprising adipose-derived stem cells.